

## Biochemical Characterization of Sfh-I, a Subclass B2 Metallo- $\beta$ -Lactamase from *Serratia fonticola* UTAD54<sup>∇</sup>

Fátima Fonseca,<sup>1,2\*</sup> Christopher J. Arthur,<sup>3</sup> Elizabeth H. C. Bromley,<sup>3†</sup>  
Bart Samyn,<sup>4</sup> Pablo Moerman,<sup>4</sup> Maria José Saavedra,<sup>5</sup>  
António Correia,<sup>1</sup> and James Spencer<sup>2\*</sup>

CESAM & Department of Biology, University of Aveiro, 3810-193 Aveiro, Portugal<sup>1</sup>; School of Cellular and Molecular Medicine, University of Bristol Medical Sciences Building, University Walk, Bristol BS8 1TD, United Kingdom<sup>2</sup>; School of Chemistry, University of Bristol, Cantock's Close, Bristol BS8 1TS, United Kingdom<sup>3</sup>; Laboratory of Protein Biochemistry and Biomolecular Engineering, Department of Biochemistry, Physiology and Microbiology, Ghent University, Ghent, Belgium<sup>4</sup>; and CECAV, Department of Veterinary Science, University of Trás-os-Montes e Alto Douro, 5001-801 Vila Real, Portugal<sup>5</sup>

Received 1 April 2011/Returned for modification 3 July 2011/Accepted 19 August 2011

**The subclass B2 metallo- $\beta$ -lactamase (MBL) Sfh-I from *Serratia fonticola* UTAD54 was cloned and overexpressed in *Escherichia coli*. The recombinant protein binds one equivalent of zinc, as shown by mass spectrometry, and preferentially hydrolyzes carbapenem substrates. However, compared to other B2 MBLs, Sfh-I also shows limited hydrolytic activity against some additional substrates and is not inhibited by a second equivalent of zinc. These data confirm Sfh-I to be a subclass B2 metallo- $\beta$ -lactamase with some distinctive properties.**

Metallo- $\beta$ -lactamases (MBLs) are zinc-dependent enzymes of growing clinical concern (23). They hydrolyze carbapenems, which are key antibiotics for resistant Gram-negative bacteria, and are insensitive to serine  $\beta$ -lactamase inhibitors (7). Sequence information divides MBLs into three subclasses, B1, B2, and B3 (13). Subclass B2, the least studied, includes CphA (16, 20), ImiS (6, 24), and AsbM1 (25) from *Aeromonas* spp. and Sfh-I (18) from the occasional pathogen *Serratia fonticola* (4, 8, 14, 17). These are monozinc enzymes that strongly prefer carbapenem substrates. Sfh-I (18) and a class A carbapenemase, SFC-1 (12, 15), are specific to *S. fonticola* strain UTAD54. Sfh-I diverges markedly (58% ImiS and 60% CphA sequence identity) from the *Aeromonas* B2 MBLs (18). Here we expressed, purified, and biochemically characterized recombinant Sfh-I.

The complete *bla*<sub>Sfh-I</sub> gene (GenBank accession no. AF197943) (primers SfhFv4 [5'-GGATCCCATATGAATAT TAAATATTTATTTACGGCTG-3'] and SfhRv2 [5'-GTGCT CGAGTTACTTAGCGCCTTCTCAAGC-3']) and the fragment encoding the expected mature protein (nucleotides 55 to 759; primers SfhFv3 [5'-GGATCCCATATGTCTGAAAAA ACTTAACGCTTACC-3'] and SfhRv2) were amplified by

PCR; the products were ligated into vector pET-26b (Novagen), generating plasmids pSfh-Iv4 and pSfh-Iv3, respectively, and the constructs were sequenced. Protein was expressed in *Escherichia coli* BL21 Star (DE3) (Invitrogen) (37°C, M9Y medium, 50  $\mu$ g/ml kanamycin, overnight induction [1 mM IPTG] at 25°C) and purified by anion exchange (Q-Sepharose; 50 mM Tris-HCl, 100  $\mu$ M ZnCl<sub>2</sub>, pH 8.5) and size exclusion (Superdex 75; 50 mM HEPES, pH 7.0) chromatography, yielding approximately 50 mg/liter Sfh-I at >95% purity as adjudged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).

Sfh-I molecular mass and metal content characteristics were investigated by electrospray mass spectrometry (QStar XL qTOF system, positive-ion mode, nanoliter/minute sample delivery, Nanomate source [0.3 lb/in<sup>2</sup>, 1.4 kV]). The mass obtained for Sfh-Iv3 under denaturing conditions (26,136 Da; Fig. 1A) agreed with the value predicted (26,134 Da) from the sequence after removal of the N-terminal methionine. A similar result for Sfh-Iv4 confirmed removal of a 21-amino-acid signal peptide (18). Additional peaks may represent oxidized (26,136 + 16 = 26,152 Da [observed]) and subsequently hydrated (26,152 + 18 = 26,170 Da [observed]) adducts. In the native spectrum (Fig. 1B), peaks at 26,201 Da (26,136 + 65 Da), 26,218 Da (26,152 + 66 Da), and 26,239 Da (26,170 + 69 Da) indicate additions of one equivalent of zinc (65 Da) to species found under denaturing conditions. Thus, as isolated, the Sfh-I was primarily mononuclear, as observed for CphA and ImiS (6, 16) and in the Sfh-I crystal structures (Protein Data Bank [PDB] accession no. 3Q6V and 3SD9) (11), and typical of a B2 MBL.

$\beta$ -Lactam hydrolysis (50 mM HEPES, pH 7.0 [25°C]) was investigated as described previously (19) (Table 1). Experiments were performed in triplicate, recording data points every

\* Corresponding author. Mailing address for Fátima Fonseca: CESAM, Department of Biology, University of Aveiro, 3810-193 Aveiro, Portugal. Phone: (351) 234 370 970. Fax: (351) 234 372 587. E-mail: ffonseca@ua.pt. Mailing address for James Spencer: School of Cellular and Molecular Medicine, University of Bristol Medical Sciences Building, University Walk Bristol BS8 1TD, United Kingdom. Phone: (44) (0) 117 331 2084. Fax: (44) (0) 117 331 2091. E-mail: Jim.Spencer@bristol.ac.uk.

† Present address: Department of Physics, Durham University, South Road, Durham DH1 3LE, United Kingdom.

<sup>∇</sup> Published ahead of print on 29 August 2011.




FIG. 1. Mass spectra of recombinant Sfh-I. (A) Spectrum acquired under denaturing conditions. (B) Spectrum acquired under nondenaturing (native) conditions.

3 to 4 s for 20 to 30 min and adjusting concentrations to ensure measurement of the linear phase of the reaction. Sfh-I efficiently hydrolyzes carbapenems (imipenem and meropenem  $k_{cat}/K_m > 10^5 \text{ M}^{-1} \text{ s}^{-1}$ ) but resembles other B2 MBLs in its low affinity ( $K_m > 300 \text{ }\mu\text{M}$ ) and catalytic efficiency ( $k_{cat}/K_m \leq 10^3 \text{ M}^{-1} \text{ s}^{-1}$ ) for many penicillins and cephalosporins (9, 10, 20, 22, 24, 25). This is consistent with previous data showing that Sfh-I expression in *E. coli* substantially elevated carbapenem MICs but had little effect on those for other  $\beta$ -lactams (18). Sfh-I hydrolyzed benzylpenicillin, cefotaxime, ceftazidime, and sulbactam, but kinetic parameters for these substrates could not be derived due to low affinities. Unexpectedly, Sfh-I (0.01  $\mu\text{M}$ ) hydrolyzed cefepime (against which 0.5  $\mu\text{M}$  CphA shows no detectable activity [9]) with relatively high efficiency. While differences between laboratories and experimental conditions make comparison with data from previously

characterized B2 MBLs difficult, we note that the low affinity of Sfh-I for penicillins is consistent with results seen with other enzymes (possibly excepting AsbM1) and that higher  $k_{cat}$  but weaker  $K_m$  values for hydrolysis of meropenem, compared to imipenem, may be a general property of subclass B2 MBLs.

CphA is inactivated by ceftoxitin, moxalactam, and other cephalosporins with good 3' leaving groups (26). Cephalosporin degradation products also inhibit the *Bacillus cereus* B1 MBL BcII (1). Whereas Sfh-I hydrolyzes ceftoxitin, moxalactam, and cephalothin with low efficiency (Table 1), at higher concentrations each inhibited imipenem and nitrocefin hydrolysis. Interaction of Sfh-I with these compounds and their hydrolysis products was investigated. Although the mode of inhibition by the intact compounds was unclear, nitrocefin hydrolysis assays showed that preincubation with cephalothin or its hydrolysis product (purified by centrifugal filtration after

TABLE 1. Kinetic parameters of purified Sfh-I  $\beta$ -lactamase and comparison with other B2 metallo- $\beta$ -lactamases<sup>a</sup>

Substrate	$k_{cat}$ ( $\text{s}^{-1}$ )				$K_m$ ( $\mu\text{M}$ )				$k_{cat}/K_m$ ( $\text{M}^{-1} \text{ s}^{-1}$ )			
	Sfh-I	CphA	AsbM1	ImiS	Sfh-I	CphA	AsbM1	ImiS	Sfh-I	CphA	AsbM1	ImiS
Ampicillin	$9.5 \pm 1.11$	$<0.01^b$	0.13	1.1	$676 \pm 187$	$2,500^b$	65	510	$1.41 \times 10^4$	$<4^b$	$7.5 \times 10^3$	$2.2 \times 10^4$
Benzylpenicillin	ND	0.03	1.2	0.53	$>1,500$	870	160	250	ND	35	$2.0 \times 10^3$	$2.1 \times 10^3$
Carbencillin	$9.15 \pm 1.58$	$10^f$	0.44	0.5	$1,280 \pm 363$	$500^d$	28	260	$7.18 \times 10^3$	$2.0 \times 10^{4d}$	$1.6 \times 10^4$	$2.1 \times 10^3$
Nitrocefin	$0.06 \pm 0.003$	0.0028	$\leq 0.02$	$0.024^g$	$106 \pm 13.4$	1,200	ND	$51^g$	$5.7 \times 10^2$	2.5	ND	$4.0 \times 10^{3g}$
Cephaloridine	$8.22 \times 10^{-5} \pm 1.46 \times 10^{-5}$	$<0.006$	$\leq 0.06$	NH	$335 \pm 124.0$	$\sim 6,000$	ND	NH	$2.46 \times 10^{-1}$	$<1$	ND	NH
Cephalothin	ND <sup>h</sup>	NR	NR	NR	$84^i$	NR	NR	NR	ND	NR	NR	NR
Cefotaxime	ND	$>0.0002^b$	NR	NH	$>1,000$	$>100^b$	NR	NH	ND	$2^b$	NR	NH
Ceftazidime	ND	NR	NR	NR	$>500$	NR	NR	NR	ND	NR	NR	NR
Ceftoxitin	$0.032 \pm 0.00094$	$0.02^e$	$\leq 0.06$	NH	$99 \pm 7$	$615^e$	ND	NH	$3.23 \times 10^2$	$33^e$	ND	NH
Cefepime	$0.64 \pm 0.073$	NH	NR	NR	$202 \pm 43.7$	NH	NR	NR	$3.16 \times 10^3$	NH	NR	NR
Moxalactam	$0.017 \pm 0.0012$	NR	NR	NH	$91 \pm 14$	NR	NR	NR	$1.87 \times 10^2$	$5.6^e$	NR	NH
Sulbactam	ND	$0.12^c$	NR	NH	$>1,000$	$37^c$	NR	NH	ND	$3.2 \times 10^{3c}$	NR	NH
Imipenem	$51 \pm 2.8$	1,200	71	$350^f$	$79.2 \pm 11.2$	340	230	$100^f$	$6.42 \times 10^5$	$3.5 \times 10^6$	$3.1 \times 10^5$	$9.1 \times 10^{5f}$
Meropenem	$109 \pm 9.5$	3,100	220	$296^g$	$215 \pm 47.0$	1,340	630	$308^g$	$5.05 \times 10^5$	$2.3 \times 10^6$	$3.5 \times 10^5$	$3.3 \times 10^{6g}$

<sup>a</sup> Kinetic data displayed for CphA, AsbM1, and ImiS as reported by Vanhove et al. (22), Yang and Bush (25) and Walsh et al. (24), respectively, except where otherwise indicated. ND, values could not be determined; NH, no hydrolysis detected; NR, not reported.

<sup>b</sup> As reported by Bebrone et al. (2).

<sup>c</sup> As reported by Felici et al. (10).

<sup>d</sup> As reported by Segatore et al. (20).

<sup>e</sup> As reported by Zervosen et al. (26).

<sup>f</sup> As reported by Sharma et al. (21).

<sup>g</sup> As reported by Crawford et al. (6).

<sup>h</sup> Value could not be determined due to inhibition at higher concentrations.

<sup>i</sup>  $K_i$  value determined from inhibition of nitrocefin hydrolysis.




FIG. 2. Effect of additional zinc on Sfh-I. (A) Change in Sfh-I intrinsic (tryptophan) fluorescence as a function of zinc concentration (50 mM HEPES, pH 7.0; 25 $^{\circ}C$ ; excitation, 280 nm; emission, 341 nm). The solid line represents a fit of nitrocefina data to a two-site hyperbola model, with  $Y$  (fluorescence) =  $Y_2 \times [Zn^{2+}]/(K_{d2} + [Zn^{2+}]) + Y_3 \times [Zn^{2+}]/(K_{d3} + [Zn^{2+}])$ , where  $Y_2$  and  $Y_3$  represent the maximal fluorescence changes associated with binding of a second and third zinc equivalent, corresponding to  $K_{d2}$  ( $95 \pm 14 \mu$ M) and  $K_{d3}$  ( $2,300 \pm 870 \mu$ M), respectively. (B) Effect of added zinc on  $k_{cat}/k_{cat0}$  (ratio of  $k_{cat}$  at a given zinc concentration to  $k_{cat0}$  determined in the absence of excess zinc) for nitrocefina and imipenem hydrolysis. The solid line represents a fit of nitrocefina data to  $k_{cat}/k_{cat0} = (K + \alpha \times [Zn^{2+}])/([Zn^{2+}] + K)$ , where  $\alpha$  represents the value of this ratio when the zinc concentration is at a saturating level (22). (C) Far-UV circular dichroism spectra (10 mM phosphate, pH 7.0; 25 $^{\circ}C$ ; 1-mm cuvette) of Sfh-I (8.5  $\mu$ M) in the absence (solid line) and presence (dotted line) of 1 mM  $Zn^{2+}$ . (D) Second derivatives of plots of ellipticity (220 nm) against temperature for thermal unfolding of Sfh-I (8.5  $\mu$ M) in the absence (solid line) and presence (dotted line) of 1 mM  $Zn^{2+}$ .

hydrolysis using IMP-1  $\beta$ -lactamase) led to time-dependent inactivation. Loss of Sfh-I activity correlated with cephalothin hydrolysis, indicating that the hydrolysis product likely represents the inhibitory species. Incubating Sfh-I (3.6  $\mu$ M; 18 h; 25 $^{\circ}C$ ; 50 mM HEPES, pH 7.0) with various hydrolysis products (1 mM) reduced hydrolysis of 200  $\mu$ M imipenem by 13% (cefotaxime), 36% (cephalothin), and 94% (moxalactam). The level of activity of cephalothin-treated samples remained at 54% of the control level, even after overnight dialysis, suggesting inactivation by enzyme modification. Unfortunately, mass spectrometry failed to identify the inhibitory species; while all expected Sfh-I-derived peptides were detected, modified fragments were not, suggesting a labile inhibitory complex. Previous workers suggested that the moxalactam hydrolysis product covalently binds the CphA Cys-221 thiol (26). Association of Cys-221 with the thiol of an opened dihydrothiazine ring of the hydrolyzed cephalosporin (1), or addition to the exomethylene formed upon elimination of the 3' leaving group, could also explain the cephalothin inactivation of Sfh-I.

CphA is most active with a single tightly bound zinc ion ( $K_{d1} < 20$  nM) and weakly binds a second, inhibitory zinc ( $K_{d2} = 46 \mu$ M) (16). We used fluorescence spectroscopy (Jobin Yvon FluoroLog) to investigate the Sfh-I-zinc interaction. Titration of as-isolated (monozinc) Sfh-I with zinc (Fig. 2A) showed two distinct transitions, demonstrating binding of two further equivalents ( $K_{d2}$ ,  $95 \pm 14 \mu$ M;  $K_{d3}$ ,  $2,300 \pm 870 \mu$ M). The  $K_{d2}$

value is comparable to that of binding of a second zinc to CphA (46  $\mu$ M [16]). The third, low-affinity zinc (millimolar  $K_{d3}$ ) is unlikely to be physiologically relevant. (CphA binds a third zinc at a surface site distinct from the active site [3].)

Other B2 MBLs are maximally active as monozinc enzymes, with noncompetitive inhibition by a second zinc (6, 16, 25). The effect of zinc addition on Sfh-I activity was substrate dependent (Fig. 2B). Imipenem hydrolysis was unaffected by 400  $\mu$ M zinc, while nitrocefina activity increased due to an increased  $k_{cat}$  value. The midpoint ( $K$ ) for activation ( $90 \pm 4 \mu$ M) is equivalent to  $K_{d2}$ , indicating that a second zinc activates nitrocefina activity. While zinc activates nitrocefina hydrolysis for some CphA mutants (2), and the ImiS M146I mutation abolishes zinc inhibition of imipenemase activity (5), the combination of zinc-dependent nitrocefina activity and zinc-independent imipenemase activity was not previously described. Circular dichroism spectroscopy (Jasco-J810 spectropolarimeter) showed that the presence of a second zinc induced a small increase in Sfh-I secondary structure (Fig. 2C) with little effect on thermal stability ( $T_m$  for Sfh-I unfolding, 60 $^{\circ}C$ ; in 1 mM zinc, 58 $^{\circ}C$ ; Fig. 2D).

In conclusion, Sfh-I is a monozinc enzyme with a strong preference for carbapenems, confirming it to be a B2 MBL and these to be common properties of the members of this subgroup. However, Sfh-I differs from CphA, the most studied B2 MBL, in its activity toward cefepime and in the effect of addi-

tional zinc, indicating that not all B2 enzymes are inactivated by excess zinc. Further investigations should establish the basis for these differences.

The work was supported by the Fundação para a Ciência e a Tecnologia (Portugal; Ph.D. grant BD/30490/2006 to F.F.).

We thank D. N. Woolfson (School of Chemistry, University of Bristol) for access to the spectrapolarimeter.

#### REFERENCES

1. Badarau, A., A. Llinas, A. P. Laws, C. Damblon, and M. I. Page. 2005. Inhibitors of metallo- $\beta$ -lactamase generated from  $\beta$ -lactam antibiotics. *Biochemistry* **44**:8578–8589.
2. Bebrone, C., et al. 2005. Dramatic broadening of the substrate profile of the *Aeromonas hydrophila* CphA metallo- $\beta$ -lactamase by site-directed mutagenesis. *J. Biol. Chem.* **280**:28195–28202.
3. Bebrone, C., et al. 2009. The structure of the dizinc subclass B2 metallo- $\beta$ -lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site. *Antimicrob. Agents Chemother.* **53**:4464–4471.
4. Bollet, C., M. Gannier, J. M. Sainty, P. Orhesser, and P. De Micco. 1991. *Serratia fonticola* isolated from a leg abscess. *J. Clin. Microbiol.* **29**:834–835.
5. Costello, A. L., N. P. Sharma, K. W. Yang, M. W. Crowder, and D. L. Tierney. 2006. X-ray absorption spectroscopy of the zinc-binding sites in the class B2 metallo- $\beta$ -lactamase ImiS from *Aeromonas veronii* bv. *sobria*. *Biochemistry* **45**:13650–13658.
6. Crawford, P. A., et al. 2004. Over-expression, purification, and characterization of metallo- $\beta$ -lactamase ImiS from *Aeromonas veronii* bv. *sobria*. *Protein Expr. Purif.* **36**:272–279.
7. Crowder, M. W., J. Spencer, and A. J. Vila. 2006. Metallo- $\beta$ -lactamases: novel weaponry for antibiotic resistance in bacteria. *Acc. Chem. Res.* **39**:721–728.
8. Farmer, J. J., et al. 1985. Biochemical identification of new species and biogroups of Enterobacteriaceae isolated from clinical specimens. *J. Clin. Microbiol.* **21**:46–76.
9. Felici, A., and G. Amicosante. 1995. Kinetic analysis of extension of substrate specificity with *Xanthomonas maliophilia*, *Aeromonas hydrophila*, and *Bacillus cereus* metallo- $\beta$ -lactamases. *Antimicrob. Agents Chemother.* **39**:192–199.
10. Felici, A., et al. 1993. An overview of the kinetic parameters of class B  $\beta$ -lactamases. *Biochem. J.* **291**:151–155.
11. Fonseca, F., E. H. C. Bromley, M. J. Saavedra, A. Correia, and J. Spencer. 2011. Crystal structure of *Serratia fonticola* Sfh-I: activation of the nucleophile in mono-zinc metallo- $\beta$ -lactamases. *J. Mol. Biol.* **411**:951–959.
12. Fonseca, F., et al. 2007. Biochemical characterization of SFC-1, a class A carbapenem-hydrolyzing  $\beta$ -lactamase. *Antimicrob. Agents Chemother.* **51**:4512–4514.
13. Galleni, M., et al. 2001. Standard numbering scheme for class B  $\beta$ -lactamases. *Antimicrob. Agents Chemother.* **45**:660–663.
14. Gorret, J., et al. 2009. Childhood delayed septic arthritis of the knee caused by *Serratia fonticola*. *Knee* **16**:512–514.
15. Henriques, I., A. Moura, A. Alves, M. J. Saavedra, and A. Correia. 2004. Molecular characterization of a carbapenem-hydrolyzing class A  $\beta$ -lactamase, SFC-1, from *Serratia fonticola* UTAD54. *Antimicrob. Agents Chemother.* **48**:2321–2324.
16. Hernandez Valladares, M., et al. 1997. Zn(II) dependence of the *Aeromonas hydrophila* AE036 metallo- $\beta$ -lactamase activity and stability. *Biochemistry* **36**:11534–11541.
17. Pfyffer, G. E. 1992. *Serratia fonticola* as an infectious agent. *Eur. J. Clin. Microbiol. Infect. Dis.* **11**:199–200.
18. Saavedra, M. J., et al. 2003. Sfh-I, a subclass B2 metallo- $\beta$ -lactamase from a *Serratia fonticola* environmental isolate. *Antimicrob. Agents Chemother.* **47**:2330–2333.
19. Samuelsen, O., M. Castanheira, T. R. Walsh, and J. Spencer. 2008. Kinetic characterization of VIM-7, a divergent member of the VIM metallo- $\beta$ -lactamase family. *Antimicrob. Agents Chemother.* **52**:2905–2908.
20. Segatore, B., O. Massidda, G. Satta, D. Setacci, and G. Amicosante. 1993. High specificity of cphA-encoded metallo- $\beta$ -lactamase from *Aeromonas hydrophila* AE036 for carbapenems and its contribution to  $\beta$ -lactam resistance. *Antimicrob. Agents Chemother.* **37**:1324–1328.
21. Sharma, N. P., et al. 2006. Mechanistic studies on the mononuclear ZnII-containing metallo- $\beta$ -lactamase ImiS from *Aeromonas sobria*. *Biochemistry* **45**:10729–10738.
22. Vanhove, M., et al. 2003. Role of Cys221 and Asn116 in the zinc-binding sites of the *Aeromonas hydrophila* metallo- $\beta$ -lactamase. *Cell. Mol. Life Sci.* **60**:2501–2509.
23. Walsh, T. R. 2010. Emerging carbapenemases: a global perspective. *Int. J. Antimicrob. Agents* **36**:S8–S14.
24. Walsh, T. R., S. Gamblin, D. C. Emery, A. P. MacGowan, and P. M. Bennett. 1996. Enzyme kinetics and biochemical analysis of ImiS, the metallo- $\beta$ -lactamase from *Aeromonas sobria* 163a. *J. Antimicrob. Chemother.* **37**:423–431.
25. Yang, Y., and K. Bush. 1996. Biochemical characterization of the carbapenem-hydrolyzing  $\beta$ -lactamase AsbM1 from *Aeromonas sobria* AER 14M: a member of a novel subgroup of metallo- $\beta$ -lactamases. *FEMS Microbiol. Lett.* **137**:193–200.
26. Zervosen, A., et al. 2001. Inactivation of *Aeromonas hydrophila* metallo- $\beta$ -lactamase by cephamycins and moxalactam. *Eur. J. Biochem.* **268**:3840–3850.